IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Kmieciak, MacIej ^a   Payne, Kyle K ^a   Wang, Xiang Yang ^a   Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; GAMMA INTERFERON RECEPTOR; HERMES ANTIGEN; IFN GAMMA RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DOWN REGULATION; FEMALE; IMMUNOSURVEILLANCE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR ELIMINATION; TUMOR ESCAPE; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS; NEUREGULIN-1; RECEPTORS, INTERFERON; TUMOR BURDEN; TUMOR ESCAPE;

EID: 84891954837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082544     Document Type: Article

References (27)

1. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ et al. (2004) Circulating tumor cells in patients with breast cancer dormancy. ClinCancer Res 10: 8152-8162. doi:10.1158/1078-0432.CCR-04-1110.PubMed: 15623589. (Pubitemid 40053373)
2. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE et al. (2012) Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol 13: 688-695. doi:10.1016/S1470-2045(12)70209-7. PubMed: 22677156.
3. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360. doi:10.1146/annurev.immunol.22. 012703.104803. PubMed: 15032581. (Pubitemid 38680426)
4. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ et al. (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907. doi:10.1038/nature06309. PubMed: 18026089. (Pubitemid 350231320)
5. O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C et al. (2012) Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 209: 1869-1882. doi:10.1084/jem.20112738. PubMed: 22927549.
6. Kmieciak M, Knutson KL, Dumur CI, Manjili MH (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37: 675-685. doi:10.1002/eji. 200636639. PubMed: 17304628. (Pubitemid 46916934)
7. Kmieciak M, Worschech A, Nikizad H, Gowda M, Habibi M et al. (2011) CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat 126: 385-394. doi:10.1007/s10549-010-0942-8.PubMed: 20480224.
8. Bots M, van Bostelen L, Rademaker MT, Offringa R, Medema JP (2006) Serpins prevent granzyme-induced death in a species-specific manner. Immunol Cell Biol 84: 79-86. doi:10.1111/j.1440-1711.2005.01417.x. PubMed: 16405655.
9. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A et al. (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98: 11515-11520. doi:10.1073/pnas.201398198. PubMed: 11562487. (Pubitemid 32928760)
10. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A et al. (2009) Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 69: 2887-2895. doi: 10.1158/0008-5472.CAN-08-3343. PubMed: 19276366.
11. Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH et al. (1999) Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 162: 2842-2849. PubMed: 10072532. (Pubitemid 29309310)
12. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ (2008) Immune-mediated dormancy: An equilibrium with cancer. J Leukoc Biol 84: 988-993. doi:10.1189/jlb.1107774. PubMed: 18515327.
13. Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD (2006) IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 176: 905-913. PubMed: 16393975. (Pubitemid 43099688)
14. Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S et al. (2009) Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 124: 1594-1604. doi: 10.1002/ijc.24098. PubMed: 19089914.
15. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111. doi: 10.1038/35074122. PubMed: 11323675. (Pubitemid 32391043)
16. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM (2000) Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res 60: 3904-3908. PubMed: 10919667. (Pubitemid 32204585)
17. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T (2012) Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405-409. doi:10.1038/nature10803.PubMed: 22318517.
18. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA et al. (2007) Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67: 1842-1852. doi:10.1158/0008-5472.CAN-06-4038. PubMed: 17293384. (Pubitemid 46383411)
19. Sharma A, Koldovsky U, Xu S, Mick R, Roses R et al. (2012) HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118: 4354-4362. doi:10.1002/cncr.26734. PubMed: 22252842.
20. Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L et al. (2011) Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J Transl Med 9: 35-5876-9-35. PubMed: 21453513.
21. Manjili MH, Kmieciak M (2008) Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure? Int J Cancer 123: 1476-1479; author reply: 18566999.
22. Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S et al. (2009) Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: Selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 69: 8058-8066. doi: 10.1158/0008-5472.CAN-09-0834. PubMed: 19826050.
23. Lin Y, Zhong Y, Guan H, Zhang X, Sun Q (2012) CD44+/CD24-phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. J Exp Clin Cancer Res 31: 59-9966-31-59. PubMed: 22762532.
24. Sun H, Jia J, Wang X, Ma B, Di L et al. (2013) CD44+/CD24-breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. Clin Transl Oncol 15: 46-54. doi:10.1007/s12094-012-0891-2. PubMed: 22855175.
25. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM et al. (2012) CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43: 364-373. doi:10.1016/j.humpath.2011.05.005. PubMed: 21835433.
26. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B (2008) Sca-1 identifies the tumor-initiating cells in mammary tumors of BALBneuT transgenic mice. Neoplasia 10: 1433-1443. PubMed: 19048122.
27. Payne KK, Manjili MH (2012) Adaptive immune responses associated with breast cancer relapse. Arch Immunol Ther Exp (Warsz) 60: 345-350. doi:10.1007/s00005-012-0185-y. PubMed: 22911133.